Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tolbutamide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.97 |
| ▸ | LMNA | P02545 | 3/20 | 0.97 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.97 |
| ▸ | TSHR | P16473 | 2/20 | 0.97 |
| ▸ | ALB | P02768 | 1/20 | 0.97 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.97 |
| ▸ | FBP1 | P09467 | 7/20 | 0.69 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | THRB | P10828 | 1/20 | 0.61 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.61 |
| ▸ | HTR2A | P28223 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | CA12 | O43570 | 1/20 | 0.60 |
| ▸ | CA1 | P00915 | 1/20 | 0.60 |
| ▸ | CA2 | P00918 | 1/20 | 0.60 |
| ▸ | CA9 | Q16790 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tolbutamide SCHEMBL15918 | 0.98 | ALDH1A1 (1.00) | ALDH1A1LMNACYP2C9TSHRALB | |
| Tolbutamide SCHEMBL1536920 | 0.98 | ALDH1A1 (1.00) | ALDH1A1LMNACYP2C9TSHRALB | |
| Tolbutamide SCHEMBL28184306 | 0.97 | ALDH1A1 (0.97) | ALDH1A1LMNACYP2C9TSHRALB | |
| Tolbutamide SCHEMBL140363 | 0.97 | ALDH1A1 (0.97) | ALDH1A1LMNACYP2C9TSHRALB | |
| Tolbutamide SCHEMBL11356450 | 0.97 | ALDH1A1 (0.97) | ALDH1A1LMNACYP2C9TSHRALB | |
| Tolbutamide SCHEMBL4367531 | 0.97 | ALDH1A1 (0.97) | ALDH1A1LMNACYP2C9TSHRALB | |
| Tolbutamide SCHEMBL28046582 | 0.97 | ALDH1A1 (0.97) | ALDH1A1LMNACYP2C9TSHRALB | |
| Tolbutamide SCHEMBL11357518 | 0.97 | ALDH1A1 (0.97) | ALDH1A1LMNACYP2C9TSHRALB | |
| Tolbutamide SCHEMBL7551276 | 0.97 | ALDH1A1 (0.97) | ALDH1A1LMNACYP2C9TSHRALB | |
| Tolbutamide SCHEMBL8733982 | 0.96 | ALDH1A1 (0.94) | ALDH1A1LMNACYP2C9TSHRALB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240145031-A1 | Methods and devices for drug repositioning and drug repurposing as nuclear receptor modulators | Precision Medicine Lab (NL) | 2024-05-02 | — | — | US | disclosed |
| US-20210290771-A1 | ENGINEERED RECEPTOR/LIGAND SYSTEM FOR DELIVERY OF THERAPEUTIC AGENTS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2021-09-23 | — | — | US | disclosed |
| US-11000597-B2 | Engineered receptor/ligand system for delivery of therapeutic agents | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2021-05-11 | — | — | US | disclosed |
| CN-107746405-B | SYK inhibitors | 吉利德科学公司 | 2020-09-22 | — | — | CN | disclosed |
| US-10722562-B2 | Combinatorial analysis and repair | IMMUDEX APS (DK) | 2020-07-28 | — | — | US | disclosed |
| US-20180271788-A1 | VESICLE CONTAINING METALLIC NANOPARTICLE AND METHOD FOR PRODUCTION THEREOF | The United States of America, as represented by the Secretary, Department of Health and | 2018-09-27 | — | — | US | disclosed |
| US-20180015172-A1 | ENGINEERED RECEPTOR/LIGAND SYSTEM FOR DELIVERY OF THERAPEUTIC AGENTS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2018-01-18 | — | — | US | disclosed |
| CN-103271083-B | Multi-functional ionic liquid compositions | 阿拉巴马大学 | 2017-08-11 | — | — | CN | disclosed |
| US-20170216314-A1 | TOPICAL FORMULATIONS | NUVO RESEARCH INC. (CA) | 2017-08-03 | — | — | US | disclosed |
| WO-2017100500-A1 | VESICLE CONTAINING METALLIC NANOPARTICLE AND METHOD FOR PRODUCTION THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2017-06-15 | — | — | WO | disclosed |
| US-5795909-A | ANTICARCINOGENIC AND ANTITUMOR AGENTS; BREAST, COLON, OVARIANCANCERS | NEUROMEDICA, INC. (US) | 1998-08-18 | — | — | US | disclosed |
| US-5786191-A | SCREENING A DRUG TEST BY METABOLIZING THE DRUG WITH A CYTOCHROME POLYPEPTIDE | UNITED STATES OF AMERICA, THE, AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | 1998-07-28 | — | — | US | disclosed |
| WO-1997044063-A2 | DHA-PHARMACEUTICAL AGENT CONJUGATES | NEUROMEDICA, INC. (US) | 1997-11-27 | — | — | WO | disclosed |
| WO-1995030766-A1 | CLONING, EXPRESSION AND DIAGNOSIS OF HUMAN CYTOCHROME P450 2C19: THE PRINCIPAL DETERMINANT OF S-MEPHENYTOIN METABOLISM | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1995-11-16 | — | — | WO | disclosed |
| EP-0182765-B1 | ELECTROCHEMICAL CONTROLLED RELEASE DRUG DELIVERY SYSTEM | THE REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 1992-08-26 | — | — | EP | disclosed |
| US-5047429-A | Treatment of oedema | HOECHST AKTIENGESELLSCHAFT (DE) | 1991-09-10 | — | — | US | disclosed |
| US-4933178-A | Metal-based antimicrobial coating | BIOINTERFACE TECHNOLOGIES, INC. (US) | 1990-06-12 | — | — | US | disclosed |
| EP-0338415-A2 | Use of sulphonylureas in the treatment of oedema | HOECHST AKTIENGESELLSCHAFT (DE) | 1989-10-25 | — | — | EP | disclosed |
| EP-0182765-A2 | Electrochemical controlled release drug delivery system | THE REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 1986-05-28 | — | — | EP | disclosed |
| US-4585652-A | REDOX SITES ON CHARGED POLYMER | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 1986-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170216314-A1 | TOPICAL FORMULATIONS | SMURF1, SGMS1, SPTLC1 | ALDH1A1 3342/4885LMNA 2342/4885CYP2C9 3426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.